RetinalGenix Technologies Inc. (RTGN)
| Previous Close | 3.5000 |
| Open | 3.5000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 3.5000 - 3.5000 |
| 52 Week Range | 3.0000 - 9.0000 |
| Volume | |
| Avg. Volume | 6 |
| Market Cap | 62.249M |
| Beta (5Y Monthly) | -2.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy
A New Patent Granted for an Affordable and Effective Device and Method To Detect Ocular And Systemic DiseasesPETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy. The present invention relates to systems and methods for visualizing eye anatomy for dia
- GlobeNewswire
RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
PETALUMA, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has contracted with MEDsan, Inc. (“MEDsan” to provide diagnostic testing services for its Institutional Review Board (IRB) to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration, which was previously announced on October 30, 2023 (see the link.) “We are pleased to extend our service
- GlobeNewswire
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board
PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D. has joined the Company’s Medical Advisory Board. RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies. Dr. Dritschilo is a renowned educator, inventor, translational scien
